Collplant Biotechnologies Ltd Revenue Growth Rates (CLGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Collplant Biotechnologies Ltd  (NASDAQ: CLGN)
 

CLGN's Revenue Growth by Quarter and Year

Collplant Biotechnologies Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLGN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 2.37
3rd Quarter September 0.00
2nd Quarter June 0.18
1st Quarter March 0.00
FY 2.55

CLGNs Annual Revenue
Collplant Biotechnologies Ltd's Revenue in the fiscal year 2025 $ 2.37 millions
Collplant Biotechnologies Ltd's Revenue in the fiscal year 2024 $ 0.52 millions
Collplant Biotechnologies Ltd's Revenue in the fiscal year 2023 $ 10.96 millions
Collplant Biotechnologies Ltd's Revenue in the fiscal year 2022 $ 0.30 millions
Collplant Biotechnologies Ltd's Revenue in the fiscal year 2021 $ 15.64 millions




CLGN Revenue fourth quarter 2025 Y/Y Growth Comment
Collplant Biotechnologies Ltd achieved in the fourth quarter 2025, above Company average Revenue surge of 848.4% year on year, to $ 2.37 millions.

Looking into fourth quarter 2025 results within Medical Equipment & Supplies industry 4 other companies have achieved higher Revenue growth. While Collplant Biotechnologies Ltd' s Revenue doubling of 848.4% ranks overall at the positon no. 68 in the fourth quarter 2025.


CLGN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 848.4 % - - -
3rd Quarter September - 3553.33 % -98.08 % 154.72 %
2nd Quarter June - - - -
1st Quarter March - 14442.86 % -89.86 % -15.85 %
FY   -88.07 % 5681.08 % -97.73 % -

Financial Statements
Collplant Biotechnologies Ltd's fourth quarter 2025 Revenue $ 2.37 millions CLGN's Income Statement
Collplant Biotechnologies Ltd's fourth quarter 2024 Revenue $ 0.25 millions Quarterly CLGN's Income Statement


CLGN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -97.72 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -88.07 % 5681.08 % -97.73 % -


Back to CLGN Growth rate Comparisons >> Back to CLGN Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #5
Healthcare Sector #28
Overall #68

Revenue Y/Y Growth Statistics
High Average Low
3565.22 % 767.51 % -98.09 %
(Dec 31 2023)   (Dec 31 2022)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #5
Healthcare Sector #28
Overall #68
Revenue Y/Y Growth Statistics
High Average Low
3565.22 % 767.51 % -98.09 %
(Dec 31 2023)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Collplant Biotechnologies Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CLGN's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CLGN's IV. Quarter Q/Q Revenue Comment


Collplant Biotechnologies Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 2.37 $ 0.52 $ 10.96 $ 0.30 $ 15.64
Y / Y Revenue Growth (TTM) 360.39 % -95.3 % 3565.22 % -98.09 % 154.86 %
Year on Year Revenue Growth Overall Ranking # 12 # 67 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 360.39 % -95.3 % 3565.22 % -98.09 % 154.86 %
Seq. Revenue Growth (TTM) Overall Ranking # 68 # 116 # 0 # 0 # 0


Cumulative Revenue growth Comment
Although Collplant Biotechnologies Ltd's Annual Revenue growth year on year were below company's average 779.61% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 360.39% year on year, from -95.3% in Dec 31 2024.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 12, from total ranking in previous quarter at 67.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 5
Healthcare Sector # 3
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
3565.22 %
 779.61 %
-98.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 28
S&P 500 # 68
Cumulative Revenue growth Comment
Although Collplant Biotechnologies Ltd's Annual Revenue growth year on year were below company's average 779.61% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 360.39% year on year, from -95.3% in Dec 31 2024.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 12, from total ranking in previous quarter at 67.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 5
Healthcare Sector # 3
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
3565.22 %
779.61 %
-98.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 28
S&P 500 # 68




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CLGN's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Verrica Pharmaceuticals Inc 1,380.23%$ 1,380.233 millions
Cue Biopharma Inc 1,292.26%$ 1,292.259 millions
Bicycle Therapeutics Plc1,193.28%$ 1,193.285 millions
Bioadaptives Inc 1,115.27%$ 1,115.268 millions
Vivos Inc892.06%$ 892.064 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________877.57%$ 877.566 millions
Ovid Therapeutics Inc 844.74%$ 844.737 millions
Syndax Pharmaceuticals Inc 791.68%$ 791.680 millions
Abcellera Biologics Inc 788.37%$ 788.374 millions
Xilio Therapeutics Inc 693.85%$ 693.852 millions
Recursion Pharmaceuticals Inc 681.74%$ 681.742 millions
Lightwave Logic Inc 594.54%$ 594.537 millions
Vaxart Inc 586.46%$ 586.460 millions
Abeona Therapeutics Inc 581.04%$ 581.036 millions
Humacyte Inc 558.35%$ 558.354 millions
Nuvation Bio Inc 544.57%$ 544.573 millions
Nexalin Technology Inc 532.46%$ 532.455 millions
Seastar Medical Holding Corp526.87%$ 526.866 millions
Assembly Biosciences Inc 477.26%$ 477.260 millions
Renovorx Inc 453.49%$ 453.488 millions
Legend Biotech Corporation451.62%$ 451.624 millions


About Collplant Biotechnologies Ltd Revenue Growth Rates (CLGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Collplant Biotechnologies Ltd (CIK 1631487).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-034393
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Collplant Biotechnologies Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.